Survival in gastric and esophageal cancers in the Nordic countries through a half century

Author:

Hemminki Kari12ORCID,Tichanek Filip13,Försti Asta45,Hemminki Otto67,Hemminki Akseli78ORCID

Affiliation:

1. Biomedical Center, Faculty of Medicine Charles University Pilsen Czech Republic

2. Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany

3. Institute of Pathological Physiology, Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

4. Hopp Children's Cancer Center (KiTZ) Heidelberg Germany

5. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) German Cancer Consortium (DKTK) Heidelberg Germany

6. Department of Urology Helsinki University Hospital and University of Helsinki Helsinki Finland

7. Cancer Gene Therapy Group, Translational Immunology Research Program University of Helsinki Helsinki Finland

8. Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Abstract

AbstractBackgroundGastric cancer (GC) and esophageal cancer (EC) are among the most fatal cancers and improving survival in them is a major clinical challenge. Nordic cancer data were recently released up to year 2019. These data are relevant for long‐term survival analysis as they originate from high‐quality national cancer registries from countries with practically free access to health care, thus documenting ‘real‐world’ experience for entire populations.Patients/MethodsData were obtained for Danish (DK), Finnish (FI), Norwegian (NO), and Swedish (SE) patients from the NORDCAN database from years 1970 through 2019. Relative 1‐ and 5‐year survival were analyzed, and additionally the difference between 1‐ and 5‐year survival was calculated as a measure of trends between years 1 and 5 after diagnosis.ResultsRelative 1‐year survival for Nordic men and women in GC was 30% in period 1970–74 and it increased close to 60%. Early 5‐year survival ranged between 10 and 15% and the last figures were over 30% for all women and NO men while survival for other men remain below 30%. Survival in EC was below that in GC, and it reached over 50% for 1‐year survival only for NO patients; 5‐year survival reached over 20% only for NO women. For both cancers, the difference between 1‐ and 5‐year survival increased with time. Survival was worst among old patients.ConclusionGC and EC survival improved over the 50‐year period but the increase in 5‐year survival was entirely explained by gains in 1‐year survival, which improved at an accelerated pace in EC. The likely reasons for improvements are changes in diagnosis, treatment, and care. The challenges are to push survival past year 1 with attention to old patients. These cancers have a potential for primary prevention through the avoidance of risk factors.

Funder

Horizon 2020 Framework Programme

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference33 articles.

1. Gastric cancer

2. Global Burden of 5 Major Types of Gastrointestinal Cancer

3. A global assessment of recent trends in gastrointestinal cancer and lifestyle‐associated risk factors

4. Familial risks and proportions describing population landscape of familial cancer;Hemminki K;Cancer,2021

5. Familial risks for liver, gallbladder and bile duct cancers and for their risk factors in Sweden, a low‐incidence country;Hemminki K;Cancer,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3